Pharmacotherapy and child psychiatry: Is there a way forward?

Advances in Psychiatric Treatment

Volumn 14, Issue 1, 2008, Pages 10-16

  James, A ^a,b  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BULIMIA; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; COGNITIVE THERAPY; COMMUNITY CARE; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOSIS; PSYCHOSOCIAL CARE; PUBLICATION; RISK REDUCTION; SUICIDAL IDEATION; SUICIDE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 58049111756     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.107.003830     Document Type: Article

References (49)

1. American Academy of Child and Adolescent Psychiatry (1997) Practice parameters for the assessment and treatment of children, adolescents, and adults with attentiondeficit/hyperactivity disorder. Journal of the American Academy Child and Adolescent Psychiatry, 36 (suppl. 10), 85S-112S.
2. Armenteros, J., Lewis, J. & Davalos, M. (2007) Risperidone augmentation for treatment-resistant aggression in attention-deficit/ hyperactivity disorder: a placebo-controlled pilot study. Journal of the American Academy Child and Adolescent Psychiatry, 46, 558-565.
3. Association of the British Pharmaceutical Industry (2007) 'Information & statistics'. ABPI. http://www.abpi.org.uk/information/default.asp
4. Bridge, J., Iyengar, S., Salary, C., et al (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 297, 1683-1696.
5. Campbell, E., Gruen, R., Mountford, J., et al (2007) A national survey of physician-industry relationships. New England Journal of Medicine, 356, 1742-1750.
6. Crenshaw, T., Kavale, K., Forness, S., et al (1999) Attention deficit hyperactivity disorder and the efficacy of stimulant medication: a metaanalysis. Advances in Learning and Behavioral Disabilities, 13, 135-165.
7. De Veaugh-Geiss, J., March, J., Shapiro, M., et al (2006) Child and Adolescent Psychopharmacology New Millennium: a workshop for academia, industry, and government. Journal of the American Academy Child and Adolescent Psychiatry, 45, 261-270.
8. Faraone, S. & Biederman, J. (2002) Efficacy of Adderall® for attention-deficit/hyperactivity disorder: a meta-analysis. Journal of Attention Disorders, 6, 69-75.
9. Food and Drug Administration (1998) International Conference on Harmonisation: guidance on data elements for transmission of individual case safety reports. Federal Register, 63, 2396-2404.
10. Friedman, R. & Leon, A. (2007) Expanding the Black Box - Depression, Antidepressants, and the Risk of Suicide. New England Journal of Medicine, 356, 2343-2346.
11. Gibbons, R., Hur, K., Bhaumik, D., et al (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry, 163, 1898-1904.
12. Goodwin, G. (2007) Conflicting interests and doing right. World Psychiatry, 6, 25-26.
13. Goodyer, I., Dubicka, B., Wilkinson, P., et al (2007) Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ, 335, 142. doi: 10.1136/bmj.39224.494340.55
14. Hamilton, B., Minino, A., Martin, J., et al (2007) Annual summary of vital statistics: 2005. Pediatrics, 119, 345-360.
15. Hammad, T., Laughren, T., Racoosin, J. (2006) Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332-339.
16. Healy, D., Langmaak, C. & Savage, M. (1999) Suicide in the course of the treatment of depression. Journal of Psychopharmacology, 13, 94-99.
17. Hennessy, S. & Strom, B. (2007) PDUFA reauthorization - drug safety's golden moment of opportunity? New England Journal of Medicine, 356, 1703-1704.
18. Hughes, C., Emslie, G., Crismon, L., et al (2007) Texas children's medication algorithm project: update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. Journal of the American Academy Child and Adolescent Psychiatry, 46, 667-686.
19. Institute of Medicine of the National Academies (2006) The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press.
20. James, A. (2005) The use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Epidemiologia e Psichiatria Sociale, 14, 63-66.
21. Jensen, P., Arnold, L., Swanson, J., et al (2007a) 3-year follow-up of the NIMH MTA study. Journal of the American Academy Child and Adolescent Psychiatry, 46, 989-1002.
22. Jensen, P., Youngstrom, E., Steiner, H., et al (2007b) Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. Journal of the American Academy Child and Adolescent Psychiatry, 46, 309-322.
23. Keech, A., Gebski, V. & Pike, R. (eds) (2007) Interpreting and Reporting Clinical Trials. A Guide to the CONSORT Statement and the Principles of Randomised Controlled Trials. MJA Books.
24. Kent, A. & Mintes, B. (2007) Should patient groups accept money from drug companies? BMJ, 334, 934-935.
25. Laine, C. & Horton, R. (2007) Clinical trial registration. BMJ, 334, 1177-1178.
26. Libby, A., Brent, D., Morrato, E., et al (2007) Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry, 164, 884-891.
27. March, J. S., Silva, S. G., Compton, S., et al (2004a) The Child and Adolescent Psychiatry Trials Network (CAPTN). Journal of the American Academy Child and Adolescent Psychiatry, 43, 515-518.
28. March, J., Silva, S., Petrycki, S., et al (2004b) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA, 292, 807-820.
29. March, J., Kratochvil C., Clarke, G., et al (2004c) AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. Journal of the American Academy Child and Adolescent Psychiatry, 43, 1046-1056.
30. March, J. S., Silva, S. G., Compton, S., et al (2005) The case for practical clinical trials in psychiatry. American Journal of Psychiatry, 162, 836-846.
31. March, J., Silva, S., Vitiello, B., et al (2006) The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. Journal of the American Academy Child and Adolescent Psychiatry, 45, 1393-1403.
32. Majewicz-Hefley, A. & Carlson, J. (2007) A meta-analysis of combined treatments for children diagnosed with ADHD. Journal of Attention Disorders, 10, 239-250.
33. McCracken, J., McGough, J., Shah, B., et al (2002) Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
34. Morgan, S. & Taylor, E. (2007) Antipsychotic drugs in children with autism. BMJ, 334, 1069-1070.
35. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
36. MTA Co-operative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics, 113, 754-761.
37. National Collaborating Centre for Mental Health (2004) Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. British Psychological Society.
38. National Collaborating Centre for Mental Health (2005) Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. British Psychological Society.
39. Olfson, M., Shaffer, D., Marcus, S., et al (2003) Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry, 60, 978-982.
40. Olfson, M., Blanco, C., Liu, L., et al (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry, 63, 679-685.
41. Padina G., Aman, M. & Findling R. (2006) Risperidone in the management of disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology, 16, 379-392.
42. Panorama (2007) 'Secrets of the drug trials'. BBC. http://news.bbc.co.uk/1/hi/programmes/panorama/6291773.stm
43. Pediatric OCD Treatment Study Team (2004) Cognitive-behavior therapy sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 292, 1969-1976.
44. Posner, K., Oquendo, M., Gould, M., et al (2007) Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. American Journal of Psychiatry, 164, 1035-1043.
45. Research Unit on Pediatric Psychopharmacology Anxiety Study Group (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine, 344, 1279-1285.
46. Shea, S., Turgay, A., Carroll, A., et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, 1447-1448.
47. Timimi, S. (2007) Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues. Advances in Psychiatric Treatment, 14, 3-9.
48. Vieta, E. (2007) Psychiatry: from interest in conflict to conflicts of interest. World Psychiatry, 6, 27-29.
49. Wolpert, M., Fuggle, P., Cottrell, D., et al (2006) Drawing on the Evidence: Advice for Mental Health Professionals Working with Children and Adolescents (2nd edn.) CAMHS Publications.